1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪
| 中文名称 | 1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 |
|---|---|
| 中文同义词 | 1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪;阿哆嗪;化合物 T10249;阿多拉嗪;1-(2,3-二氢苯并[B][1,4]二恶烷-5-基)-4-((5-(4-氟苯基)吡啶-3-基)甲基)哌嗪;阿哆嗪,10 MM DMSO 溶液;Adoprazine试剂;Adoprazine试剂 |
| 英文名称 | adoprazine |
| 英文同义词 | adoprazine;1-(2,3-Dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)-3-pyridinyl]methyl]piperazine;Unii-7snb18Q89d;SLV 313;SLV313;Adoprazine (SLV313);SLV 313;SLV313;SLV-313;Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)-3-pyridinyl]methyl]- |
| CAS号 | 222551-17-9 |
| 分子式 | C24H24FN3O2 |
| 分子量 | 405.46 |
| EINECS号 | |
| 相关类别 | G蛋白偶联受体&G蛋白 |
| Mol文件 | 222551-17-9.mol |
| 结构式 | ![1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 结构式](CAS/GIF/222551-17-9.gif) |
1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 性质
| 沸点 | 565.0±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.256 |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：50 mg/mL（123.32 mM；需要超声波）H2O：< 0.1 mg/mL（不溶） |
| 形态 | 粉末 |
| 酸度系数(pKa) | 6.07±0.10(Predicted) |
| 颜色 | 浅黄至黄色 |
|
5-HT 1A Receptor 9 (pEC 50 ) |
D 2 Receptor 9.3 (pA2) |
D 3 Receptor 8.9 (pA2) |
D 4 Receptor 8.0 (pKi) |
5-HT 7 Receptor 7.2 (pKi) |
5-HT 1A Receptor 9.1 (pKi) |
D 2 Receptor 8.4 (pKi) |
D 3 Receptor 8.4 (pKi) |
Adoprazine (SLV313) has high affinity at human recombinant D 2 , D 3 , D 4 , 5-HT 2B , and 5-HT 1A receptors, with pK i s of 8.4, 8.4, 8.0, 7.9 and 9.1, respectively. Adoprazine (SLV313) acts as a high potency dopamine D 2 receptor antagonist and an efficacious serotonin 5-HT 1A receptor agonist, with E max value (% effect of 10 μM 5-HT) of 73 and pK B value of 8.5 .
Adoprazine (SLV313) (0.1-10 mg/kg; p.o.; single) is sufficient to reduce extracellular 5-HT and increase dopamine levels in the nucleus accumbens in a dose- and time-dependent manner.
| Animal Model: | Male Wistar rats (275-350 g) |
| Dosage: | 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg |
| Administration: | p.o.; single |
| Result: | Led to a dose- and time-dependent increase in extracellular levels of DA, DOPAC, and HVA. In contrast, led to a reduction in 5-HT levels and no change in 5-HIAA levels. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/09/15 | HY-14782 | 1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 Adoprazine | 222551-17-9 | 1 mg | 596元 |
| 2026/09/15 | HY-14782 | 1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 Adoprazine | 222551-17-9 | 5mg | 1400元 |